GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel

Core Viewpoint - GenSight Biologics has received authorization from Israel's Ministry of Health for the early access treatment of its gene therapy candidate GS010/LUMEVOQ® for individual patients [1] Company Summary - GenSight Biologics is a biopharma company focused on developing and commercializing innovative gene therapies specifically for retinal neurodegenerative diseases and central nervous system disorders [1]